SURPASS-CVOT: A comparison of Tirzepatide and Dulaglutide
Diabetes Insights - Breakthroughs and InnovatorsShow Notes
In this weeks episode of Diabetes Insights - Breakthroughs and Innovators, experts discuss the highly anticipated SURPASS CVOT trial, a head-to-head cardiovascular outcomes study comparing tirzepatide 15 mg weekly with dulaglutide 1.5 mg weekly in people with type 2 diabetes. With over 13,000 participants, the trial demonstrates that tirzepatide provides equivalent cardioprotective benefits to dulaglutide, confirming its role in improving both glycaemic control and cardiovascular outcomes.
EASD TV Host Vivienne Parry sits with Prof. Tina Vilsbøll (EASD Honorary Secretary) and Prof. Hertzel Gerstein (EASD Independent Advisor and McMaster University) to unpack the trial’s implications for clinical practice, highlighting how outcomes trials like this inform personalised medicine, integrate care between diabetologists and cardiologists, and generate new hypotheses in areas such as liver disease, cognitive function, and obesity management. This episode underscores the growing importance of transdisciplinary approaches in diabetes care, where therapies can target multiple complications simultaneously.
Join us to understand how outcomes trials like SURPASS-CVOT are shaping guidelines, expanding treatment options, and improving care for people living with type 2 diabetes worldwide.
More from Diabetes Insights - Breakthroughs and Innovators
In this EASD TV interview, Prof. Zachary Gerhart-Hines (Novo Nordisk Foundation Center for Basic Metabolic Research), 61st EASD Minkowski Prize recipient, discusses research into the neurokinin-2 receptor (NK2R) and its potential to change how we approach weight management and metabolic health. Where many existing treatments focus on reducing food intake, NK2R activation could offer a complementary strategy by increasing energy expenditure, influencing appetite and improving insulin sensitivity.
How does exercise stimulate glucose uptake in muscle and what can this teach us about treating type 2 diabetes?
Prof. Anette-Gabriele Ziegler, this year’s Claude Bernard Prize Lecture recipient, reflects on her career in type 1 diabetes research and the evolution of our understanding of the disease.
The EASD’s first clinical practice guideline on the assessment and management of diabetes distress in adults living with type 1 or type 2 diabetes has now been published in Diabetologia.
How can people living with diabetes help shape the future of diabetes care?